Zobrazeno 1 - 10
of 43
pro vyhledávání: '"Nicos Karasavvas"'
Autor:
LaTonya D Williams, Xiaoying Shen, Sheetal S Sawant, Siriwat Akapirat, Lindsay C Dahora, Matthew Zirui Tay, Sherry Stanfield-Oakley, Saintedym Wills, Derrick Goodman, DeAnna Tenney, Rachel L Spreng, Lu Zhang, Nicole L Yates, David C Montefiori, Michael A Eller, David Easterhoff, Thomas J Hope, Supachai Rerks-Ngarm, Punnee Pittisuttithum, Sorachai Nitayaphan, Jean-Louis Excler, Jerome H Kim, Nelson L Michael, Merlin L Robb, Robert J O'Connell, Nicos Karasavvas, Sandhya Vasan, Guido Ferrari, Georgia D Tomaras, RV305 study team
Publikováno v:
PLoS Pathogens, Vol 19, Iss 5, p e1011359 (2023)
The modestly efficacious HIV-1 vaccine regimen (RV144) conferred 31% vaccine efficacy at 3 years following the four-shot immunization series, coupled with rapid waning of putative immune correlates of decreased infection risk. New strategies to incre
Externí odkaz:
https://doaj.org/article/e0502dca070d4a5f86962367ed6a51ba
Autor:
Natalie D. Collins, Shannon Beaty, Elana Wallace, Yuanzhang Li, Mark Sanborn, Yu Yang, Anima Adhikari, Paul Shabram, Kelly Warfield, Nicos Karasavvas, Robert A. Kuschner, Jun Hang
Publikováno v:
Vaccines, Vol 11, Iss 7, p 1144 (2023)
The FDA-approved Adenovirus Type 4 and Type 7 Vaccine, Live, Oral is highly effective and essential in preventing acute respiratory diseases (ARDs) in U.S. military recruits. Our study revealed the presence of a previously undetected mutation, not fo
Externí odkaz:
https://doaj.org/article/3b23e21ed396436baeff6b217e105982
Autor:
Shannon Beaty, Natalie Collins, Nicos Karasavvas, Robert Kuschner, Jun Hang, Anima Adhikari, Irina Maljkovic Berry, Christian Fung, Shannon Walls, Elena Betancourt, Jason Mendy, Michael Lock, Emma Gierman, Sean Bennett, Paul Shabram, Kelly Warfield
Publikováno v:
Vaccines, Vol 11, Iss 6, p 1091 (2023)
PXVX0047 is an investigational vaccine developed for active immunization to prevent febrile acute respiratory disease (ARD) caused by adenovirus serotypes 4 (Ad4) and 7 (Ad7). PXVX0047 consists of a modernized, plasmid-derived vaccine that was genera
Externí odkaz:
https://doaj.org/article/0566959fe7f44e8eb743ac36913023a5
Autor:
Natalie D. Collins, Anima Adhikari, Yu Yang, Robert A. Kuschner, Nicos Karasavvas, Leonard N. Binn, Shannon D. Walls, Paul C. F. Graf, Christopher A. Myers, Richard G. Jarman, Jun Hang
Publikováno v:
Vaccines, Vol 8, Iss 3, p 411 (2020)
Human adenoviruses (AdV) are mostly associated with minimal pathology. However, more severe respiratory tract infections and acute respiratory diseases, most often caused by AdV-4 and AdV-7, have been reported. The only licensed vaccine in the United
Externí odkaz:
https://doaj.org/article/8234a6b91b2449c98aeecf95680bf56f
Autor:
Siriwat Akapirat, Chitraporn Karnasuta, Sandhya Vasan, Supachai Rerks-Ngarm, Punnee Pitisuttithum, Sirinan Madnote, Hathairat Savadsuk, Surawach Rittiroongrad, Jiraporn Puangkaew, Sanjay Phogat, James Tartaglia, Faruk Sinangil, Mark S de Souza, Jean-Louis Excler, Jerome H Kim, Merlin L Robb, Nelson L Michael, Viseth Ngauy, Robert J O'Connell, Nicos Karasavvas, RV305 Study Group
Publikováno v:
PLoS ONE, Vol 13, Iss 4, p e0196397 (2018)
Sexual transmission is the principal driver of the human immunodeficiency virus (HIV) pandemic. Understanding HIV vaccine-induced immune responses at mucosal surfaces can generate hypotheses regarding mechanisms of protection, and may influence vacci
Externí odkaz:
https://doaj.org/article/b6a6cce028b540d6b3b05c44c133477e
Autor:
Susan Zolla-Pazner, Paul T. Edlefsen, Morgane Rolland, Xiang-Peng Kong, Allan deCamp, Raphael Gottardo, Constance Williams, Sodsai Tovanabutra, Sandra Sharpe-Cohen, James I. Mullins, Mark S. deSouza, Nicos Karasavvas, Sorachai Nitayaphan, Supachai Rerks-Ngarm, Punnee Pitisuttihum, Jaranit Kaewkungwal, Robert J. O'Connell, Merlin L. Robb, Nelson L. Michael, Jerome H. Kim, Peter Gilbert
Publikováno v:
EBioMedicine, Vol 1, Iss 1, Pp 37-45 (2014)
To evaluate the role of V3-specific IgG antibodies (Abs) in the RV144 clinical HIV vaccine trial, which reduced HIV-1 infection by 31.2%, the anti-V3 Ab response was assessed. Vaccinees' V3 Abs were highly cross-reactive with cyclic V3 peptides (cV3s
Externí odkaz:
https://doaj.org/article/77b7196570d64df89144922302a422ae
Autor:
Kristina K Peachman, Nicos Karasavvas, Agnes-Laurence Chenine, Robert McLinden, Supachai Rerks-Ngarm, Kaewkungwal Jaranit, Sorachai Nitayaphan, Punnee Pitisuttithum, Sodsai Tovanabutra, Susan Zolla-Pazner, Nelson L Michael, Jerome H Kim, Carl R Alving, Mangala Rao
Publikováno v:
PLoS ONE, Vol 10, Iss 12, p e0143895 (2015)
The gut mucosal homing integrin receptor α4β7 present on activated CD4+ T cells interacts with the HIV-1 gp120 second variable loop (V2). Case control analysis of the RV144 phase III vaccine trial demonstrated that plasma IgG binding antibodies spe
Externí odkaz:
https://doaj.org/article/38298a98fa1a4640af4c8df4503c5566
Autor:
Silvia Ratto-Kim, Mark S de Souza, Jeffrey R Currier, Nicos Karasavvas, John Sidney, Morgane Rolland, Anais Valencia-Micolta, Sirinan Madnote, Alessandro Sette, Sorachai Nitayaphan, Punnee Pitisuttuthum, Jaranit Kaewkungwal, Supachai Rerks-Ngarm, Robert O'Connell, Nelson Michael, Merlin L Robb, Mary Marovich, Jerome H Kim
Publikováno v:
PLoS ONE, Vol 10, Iss 2, p e0115582 (2015)
We performed fine epitope mapping of the CD4+ responses in the ALVAC-HIV-AIDSVAX B/E prime-boost regimen in the Thai Phase III trial (RV144). Non-transformed Env-specific T cell lines established from RV144 vaccinees were used to determine the fine e
Externí odkaz:
https://doaj.org/article/3f48103a5af34f3c907fa9c1c7b22e76
Autor:
Boonrat Tassaneetrithep, Doreen Tivon, James Swetnam, Nicos Karasavvas, Nelson L Michael, Jerome H Kim, Mary Marovich, Timothy Cardozo
Publikováno v:
PLoS ONE, Vol 9, Iss 9, p e108446 (2014)
The peptide segment of the second variable loop of HIV-1 spanning positions 166-181 harbors two functionally important sites. The first, spanning positions 179-181, engages the human α4β7 integrin receptor which is involved in T-cell gut-homing and
Externí odkaz:
https://doaj.org/article/c9a7733b36254fe790fc088138c73c5f
Autor:
Susan Zolla-Pazner, Allan C deCamp, Timothy Cardozo, Nicos Karasavvas, Raphael Gottardo, Constance Williams, Daryl E Morris, Georgia Tomaras, Mangala Rao, Erik Billings, Phillip Berman, Xiaoying Shen, Charla Andrews, Robert J O'Connell, Viseth Ngauy, Sorachai Nitayaphan, Mark de Souza, Bette Korber, Richard Koup, Robert T Bailer, John R Mascola, Abraham Pinter, David Montefiori, Barton F Haynes, Merlin L Robb, Supachai Rerks-Ngarm, Nelson L Michael, Peter B Gilbert, Jerome H Kim
Publikováno v:
PLoS ONE, Vol 8, Iss 1, p e53629 (2013)
The RV144 clinical trial of a prime/boost immunizing regimen using recombinant canary pox (ALVAC-HIV) and two gp120 proteins (AIDSVAX B and E) was previously shown to have a 31.2% efficacy rate. Plasma specimens from vaccine and placebo recipients we
Externí odkaz:
https://doaj.org/article/3f8bd381cf2f4c4e9cbc7c43ba28e406